JS105 plus other treatments for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have one of these cancers that has spread or come back: HR-positive/HER2-negative breast cancer, HER2-positive breast cancer, triple-negative breast cancer, endometrial cancer, cervical cancer, or ovarian/fallopian tube/peritoneal cancer.
- You have tried at least one prior treatment and your cancer has progressed or you couldn't tolerate the side effects.
- You are able to swallow pills whole and have good organ function (kidneys, liver, blood counts).
- You have not taken any PI3K/AKT/mTOR inhibitor before (unless your doctor says it's okay for certain groups).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug, JS107, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after at least one prior treatment. The cancer must have a specific protein called CLDN18.2 on its cells.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.